Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 2 Observational 1

Sponsor

Cancer Type

Conditions

Motor Activity 15 Neoplasms 11 Breast Neoplasms 4 Colonic Neoplasms 3 Colorectal Neoplasms 2 Smoking 1 Sedentary Behavior 1 Recurrence 1 Pulmonary Disease, Chronic Obstructive 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pain 1 Obesity 1 Neoplasm Metastasis 1 Melanoma 1 Lymphedema 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Fractures, Bone 1 Fibrosis 1 Fatigue 1 Death 1 Cardiovascular Diseases 1

Interventions

Blood Specimen Collection 14 Nivolumab 13 Ipilimumab 12 pembrolizumab 11 trametinib 9 Surveys and Questionnaires 9 Gene Expression Profiling 9 dabrafenib 8 Biopsy 6 Specimen Handling 5 Immunotherapy 5 Immunohistochemistry 5 Amplified Fragment Length Polymorphism Analysis 4 encorafenib 3 binimetinib 3 atezolizumab 3 Restraint, Physical 3 Quality of Life 3 Polymerase Chain Reaction 3 Introns 3 Flow Cytometry 3 Drug Therapy 3 Data Collection 3 tremelimumab 2 pimonidazole 2 cobimetinib 2 aldesleukin 2 Watchful Waiting 2 Vemurafenib 2 Therapeutics 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Melanoma × Exercise × Clear all

NCT03464604 2022-11-23

Melanoma Accuracy Study; Phase 2

Nova Scotia Health Authority

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡